Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619034 | 0.84 | SLC6A9 (0.48) | MKNK2SLC6A9KCNH2ICMTRORC | |
| SCHEMBL12619036 | 0.83 | AR (0.49) | MKNK2SLC6A9KCNH2ICMTAR | |
| SCHEMBL12619038 | 0.83 | NR3C1 (0.45) | MKNK2SLC6A9KCNH2RORCPTGDR2 | |
| SCHEMBL12619053 | 0.83 | TRPV4 (0.43) | MKNK2SLC6A9KCNH2MRGPRX4PTGDR2 | |
| SCHEMBL15494754 | 0.83 | SLC6A9 (0.41) | MKNK2SLC6A9KCNH2ARRORC | |
| SCHEMBL1796285 | 0.83 | RORC (0.52) | MKNK2SLC6A9KCNH2ARRORC | |
| SCHEMBL1796211 | 0.82 | SLC6A9 (0.43) | MKNK2SLC6A9KCNH2ARRORC | |
| SCHEMBL10088433 | 0.82 | AR (0.44) | MKNK2SLC6A9KCNH2ICMTAR | |
| SCHEMBL12619040 | 0.81 | SLC6A9 (0.42) | MKNK2SLC6A9KCNH2RORCPTGDR2 | |
| SCHEMBL16781415 | 0.80 | AR (0.43) | KCNH2ICMTARMRGPRX4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2003132-B1 | Oxadiazole derivatives as S1P1 agonists | ASTELLAS PHARMA INC (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-2003132-A1 | HETERO COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168159-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | MKNK2 2595/4885SLC6A9 4176/4885KCNH2 3242/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | MKNK2 2595/4885SLC6A9 4176/4885KCNH2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.